Progressive Supranuclear Palsy Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Biogen Reports Top-Line Results from Phase 2 Study of Gosuranemab in Progressive Supranuclear Palsy
CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Today, Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 2 PASSPORT study of gosuranemab (BIIB092) for progressive supranuclear palsy (PSP). The primary endpoint, as... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 13, 2019 Category: Pharmaceuticals Source Type: clinical trials
A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)
Condition: Progressive Supranuclear Palsy Interventions: Drug: UCB0107; Drug: Placebo Sponsor: UCB Biopharma S.P.R.L. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 4, 2019 Category: Research Source Type: clinical trials
A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)
Condition: Progressive Supranuclear Palsy Interventions: Drug: UCB0107; Drug: Placebo Sponsor: UCB Biopharma S.P.R.L. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 4, 2019 Category: Research Source Type: clinical trials
